ImmunoGen Inc (NASDAQ:IMGN) is a small-cap biotech stock. Biotech stocks can be particularly hard to analyze, often having negative earnings and historically posting losses, before eventually becoming profitable businesses. Success and also failures often hinge on one key drug or product. Therefore understanding the drug(s) the company is developing, or have developed, and determining the likelihood of it being brought to market is key. Forecasting revenues such a product/drug could generate as well as assessing future pipeline products helps provide an overall valuation and growth forecast. The following analysis indentifies the game changing nature of IMG's biotechnology in the ongoing battle against cancer and shows with conservative forecasts that IMGN offers significant capital upside.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|